Status:
COMPLETED
Mechanism of Action of Ocrelizumab in Multiple Sclerosis
Lead Sponsor:
University of Chicago
Conditions:
Multiple Sclerosis
Immune System Diseases
Eligibility:
All Genders
18-65 years
Brief Summary
Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and stops MS inflammation.
Detailed Description
The study will investigate immune cell subsets, and how the cells are modified by this therapy over a 1-year period in 25 subjects. Blood will be drawn at baseline, 2 weeks, 6 mo, and 12 mo. Immune s...
Eligibility Criteria
Inclusion
- All patients who are eligible for Ocrelizumab therapy based on FDA criteria
Exclusion
- All patients who are ineligible for Ocrelizumab therapy based on FDA criteria.
- Prior treatment with Alemtuzumab or stem cell therapy, or immune abnormalities that would interfere with planned tests.
- Hepatitis B and HIV infections.
- Pregnant or lactating women.
- Hypersensitivity to trial medications.
Key Trial Info
Start Date :
February 23 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 10 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03344094
Start Date
February 23 2018
End Date
April 10 2019
Last Update
February 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Chicago
Chicago, Illinois, United States, 60637